Login to Your Account

Active Biotech Shares Climb on Ipsen Milestone

By Cormac Sheridan
Staff Writer

Wednesday, May 23, 2012
Shares in Active Biotech AB climbed more than 12 percent Monday on news that the company earned a €10 million (US$12.7 million) milestone payment from its partner, Ipsen SA, after reaching the halfway point in recruitment into a 1,200-patient, Phase III registration trial of tasquinimod in metastatic castrate-resistant prostate cancer.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription